Skip to content

Ring-type Pulse Oximeter for Evaluation for Sleep Assessment Study

Ring-type Pulse Oximeter for Evaluation for Sleep Assessment Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06221124
Acronym
ROSA
Enrollment
40
Registered
2024-01-24
Start date
2020-07-15
Completion date
2023-06-12
Last updated
2024-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Architecture, Sleep-Disordered Breathing

Brief summary

Recently, various electronic lifestyle activity monitoring devices (ELAM) are increasingly commercially available. However, the quality and reliability of the data from ELAM are unclear, compared with polysomnography (PSG), which is the gold-standard sleep assessment method. Thus, combining ELAM with PSG will validate ELAM and improve its clinical and research utilization. The investigators propose to conduct this study to validate ELAM device for sleep assessment. The investigators will compare Belun Ring data collection and overnight in-lab PSG measures of Sleep-Disordered Breathing (SDB) and sleep architecture in adults with obstructive sleep apnea (OSA) symptoms. The investigators propose to recruit a total of 40 participants with symptoms of OSA. The overall accuracy, sensitivity and specificity of Belun Ring to assess SDB and sleep architecture will be validated by using PSG analysis as a gold standard.

Interventions

Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.

Sponsors

Stanford University
CollaboratorOTHER
Belun Technology Company Limited
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 to 80 years old. Ideally balanced for sex and age (18 to 80 years old) * no more than 75% of subjects in one bin of: (male, female) * no more than 50% of subjects in one age-group (18-29, 30-39, 40-49, 50-59, 60-80) * Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.) * Without any unstable medical or psychiatric co-morbidities that would be expected to interfere with the study. * If taking any medication, must be on a stable dose of medication for a month * Able to read and understand English

Exclusion criteria

* Presence of any significant systemic or unstable medical condition which could lead to difficulty complying with the protocol, suicidality, current regular use of psychiatric medications, opiates, or thyroid medications, dementia, current substance abuse, post-traumatic or psychotic disorders, bipolar disorder; any significant neurologic disease, including possible and probable dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of significant head trauma, history of alcohol or substance use disorder within the past 2 years (DSM V criteria); * If positive airway pressure (PAP) titration study or split night study (diagnostic and PAP titration study combined)

Design outcomes

Primary

MeasureTime frameDescription
Validation with gold-standard polysomnography (PSG) recording1 yearConcordance rate of bAHI from Belun Ring and apnea-hypopnea Index (AHI) from PSG

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026